Protease inhibitors

ABSTRACT

This invention relates to methods of preventing or reducing the degradation of elastin and other proteins and thereby preventing or retarding the disease states caused by said degradation by administering compounds of the formula: ##STR1## or their pharmacologically acceptable salts.

This is a continuation of application Ser. No. 664,447, filed Oct. 24,1984, which is a continuation of 492,842 filed May 9, 1983, now U.S.Pat. No. 4,499,295.

BACKGROUND OF THE INVENTION

(a) Field of the Invention

This invention in its broadest aspect relates to protease inhibitors. Inone aspect, the invention relates to certain novel methods useful inpreventing or treating disease states caused by the degradative actionof proteases on mammalian elastin and other proteins by administrationof effective amounts of compounds of Formula II. A preferred methodrelates to the inhibition of the proteases elastase and cathepsin G. Inother aspect, it relates to compounds of Formula I which are useful inpreventing or treating disease states caused by the degradative actionof proteases on mammalian elastin and other proteins.

Elastin is the functional protein component of elastic fiber tissues, acomponent of connective tissues. Elastic tissue is relatively rich inelastin and has a distinct rubber-like property. Most specifically, theligamentum nuchae and the vocal cords, the vertebral ligamenta flava,the aorta, and the pulmonary arteries of some mammals are consideredelastic tissues. Elastic cartilaginous tissues such as those present inthe ear and epiglottis are a specialized form of elastic tissue. Lung,bronchi and skin also contain elastin and are considered elastic tissue.Sandberg, et al., New England Journal of Medicine, Mar. 5, 1981,566-579.

Elastase is an elastinolytic enzyme which causes degradation andfragmentation of elastic fibers by its catalytic activity againstelastin. Elastases originate from a number of sources and can be foundin microorganisms, snake venoms and a number of mammalian cells andtissues including pancreas, polymorphonuclear leukocytes, andmacrophages. In a normally functioning mammal, elastase is required forturnover of damaged cells and the digestion of certain invadingbacteria. This invention in particular relates to the class of elastasesknown as the Serine Proteases.

Excessive elastin degradation has been associated with pulmonaryemphysema, adult respiratory-distress syndrome, arthritis,atherosclerosis, certain skin diseases, and certain inflammatoryprocesses leading to localized protein breakdown. Werb, et al., Journalof Investigative Dermatology, 79:154S-159S, (1982); Rinaldo, et al, NewEngland Journal of Medicine, 306: 900-909, (1982). By inhibitingelastase therefore it is possible to mediate, eliminate or treat a widevariety of disease conditions.

A number of inhibitors of elastase are known. Peptide chloromethylketones have been shown to be irreversible inhibitors of elastase. Butdifficulties must be considered when the in vivo use of peptidechloromethyl ketones is contemplated. The compounds are electrophilesand can react with good nucleophiles such as the thiol groups ofglutathione and various proteins. During any long term treatment withthese inhibitors, such non-specific alkylation could lead to theintroduction of new antigenetic determinants and an autoimmune responseand/or could behave similarly to the known nitrogen mustards, etc.Peptides containing aza-amino acid residues (aza peptides) are anotherclass of inhibitors. The effectiveness of aza-peptides as elastaseinhibitors depends on the rate of acylation, which in most cases isinstantaneous, and also on the rate of deacylation. As such, thesecompounds while useful tools in studying the in vitro properties ofelastase are still largely unsuitable for in vivo use.

(b) Information Disclosure

The treatment of certain disease states by inhibitors of elastase isknown as described above. One compound useful in practicing the methodof the invention is previously known as a dye agent or agent forimproving textile fibers. See Chem Abstracts: 3285-9 (1937).

SUMMARY OF THE INVENTION

The invention relates to compounds of the formula: ##STR2## wherein R₁is: (a) hydrogen; or

(b) alkyl or 1 to 6 carbon atoms, inclusive;

wherein R₂ is:

(a) hydroxy; or

(b) alkoxy of 1 to 6 carbon atoms, inclusive;

wherein R₃ is

(a) --CH(OH)R₄ ;

(b) --CH₂ R₄ ; or

(c) --CH═CHR₄ ;

wherein R₄ is alkyl of 13 to 25 carbon atoms inclusive and thepharmacologically acceptable base addition salts thereof.

This invention also relates to a method of preventing or reducing thedegradation of natural tissues in mammals by proteases which comprisesadministering an effective amount compound of the formula: ##STR3##wherein R₁ is: (a) hydrogen; or

(b) alkyl of 1 to 6 carbon atoms, inclusive;

wherein R₂ is:

(a) hydroxy; or

(b) alkoxy of 1 to 6 carbon atoms, inclusive;

wherein R₃ is:

(a) --C(O)R₄ ;

(b) --CH(OH)R₄ ;

(c) --CH₂ R₄ ; or

(d) --CH═CHR₄ ;

wherein R₄ is alkyl of 13 to 25 carbon atoms inclusive and thepharmacologically acceptable base addition salts thereof. A preferredmethod relates to the inhibition of the proteases elastase and cathepsinG.

Examples of alkyl of 1 to 6 carbon atoms inclusive are methyl, ethyl,propyl, butyl, pentyl, hexyl and the isomeric forms thereof.

Examples of alkoxy of 1 to 6 carbon atoms, inclusive, are methoxy,ethoxy, propoxy, butoxy, pentoxy, hexoxy and the isomeric forms thereof.

Examples of alkyl of 13 to 25 carbon atoms inclusive are dodecanes,dodecenes, hexadecanes, hexadecenes, pentadecanes, pentadecenes,eicosodecanes, eicosodecenes and the like, as well as their branchedchain isomers.

Salts of the acid forms of these compounds (R₁ ═H or R₂ ═OH) can beprepared by neutralization with the appropriate amount of an inorganicor organic base such as sodium hydroxide, potassium hydroxide, calciumhydroxide, magnesium hydroxide, ammonia, trialkylamine, dialkylamine,monoalkylamine, dibasic amino acids, sodium acetate, potassium benzoate,triethanol amine and like bases.

The compounds useful in practicing the method of the invention areinhibitors of leucocyte elastase and cathepsin G. Since elastase isinvolved in the breakdown of elastin and subsequently involved in anumber of disease states, a compound which blocks the action of elastasewill be useful in the management, treatment and prevention of suchdiseases. Elastase, in addition to degrading elastin, also willhydrolyse methoxysuccinyl-ala-ala-pro-val-nitroanalide (MSN), a highlyselective synthetic substance. Kakajima, K., et al., J. Biol. Chem.,254, 4027 (1979). This is useful in measuring inhibition of elastasebecause the hydrolysis of MSN is easily quantitated by measuring therelease of p-nitroaniline spectrophotometrically. Therefore, the degreeof elastase inhibition can be readily measured by noting the rate ofinhibition of the hydrolysis of MSN. The compounds of the invention aretherefore tested in vitro as follows. The rate of hydrolysis ofmethoxysuccinyl-ala-ala-pro-val-nitroanalide by human leukocyte elastaseis monitored spectrophotometrically in the presence and absence of testcompound. The inhibition of the eznymatic reaction by 20% or more istaken as positive inhibition. IC₅₀ values are then determined.

The following procedure is used to test the compounds in vivo(collagen-induced rat arthritis model). The method is based on that ofTrentham, D. E. Townes, A. S. and Kang, A. H. in J. Exp. Med. 146,857-968 and results are evaluated thereby.

Inbred female Wistar rats (200-230 G) were randomly assigned to 3 groupsof 30 animals each. Arthritis was induced by intradermal injection ofbovine nasal septum Type II collagen in incomplete Freunds adjuvant.

Drug treatment was oral, once daily in 0.5 ml carboxymethyl cellulosefrom day 0 until sacrifice:

Group I: Test compound 50-100 mg/kg/day

Group 2: Phenylbutazone 40 mg/kg/day (positive control)

Group 3: 1% V/V carboxymethyl cellulose (negative control)

(1) Physical measurements of hind paws were made for (a) swelling acrossplantar region; (b) malleolar thickening; (c) extensibility of anklejoint. Results were subject to systematic statistical evaluation.

(2) Histological examination of hind paws were made in groups of 5animals sacrificed at days 7, 14, 21 and 28. Sections were taken at 3levels through each foot and examined for indication of diseaseprogression.

During periods of active rheumatoid arthritis, vast numbers of humanneutrophils are attracted to diseased joints where they engage inphagocytosis of locally generated immune complexes and tissue debris.During the process, enzymes (primarily elastase and cathepsin G) arereleased into the joint spaces. Elastase has the capacity in thissituation to degrade synovial cartilage and collagen and contribute tojoint destruction in a synergistic process with cathepsin G. Cathepsin Galso causes conversion of angiotensin I to angiotensin II which isassociated with inflammatory processes, Reilley, C. F., et al., J. Biol.Chem., 257, 8619 (1982) and angiotensinogen to angiotensin II, Tonnesen,M. G., et al., J. Clin. Invest., 69, 25 (1982). Natural elastaseinhibitors (macro molecules such as in α₁ -proteinase inhibitor) alreadyexist in normal serum and synovial fluid and may prevent precipitousjoint destruction. Oxidation of the natural inhibitor (to the sulfoxideform) renders this material inactive. Wong, P. S. and J. Travis, BiochemBiophys. Res. Commun., 96, 1449 (1980). Exogenous smaller molecularweight inhibitors of the invention can gain access to themicro-environments within the joint space not accessible to the naturalinhibitors due to their molecular size, oxidation, charge repulsion orlipid solubility, and thereby inhibit or prevent furtherelastase-related destruction. In addition, pulmonary emphysema is adisease characterized by a progressive uninhibited proteolysis of lungtissue by enzymes such as elastase which in this case are released fromleukocytes. People who are homozygotes in an α₁ -antitrypsin deficiencyare predisposed to the disease. See, e.g., Turimo, et al., Amer. J.Med., Vol 57, pp. 493-503 (1974). The compounds of the invention couldalso be used to prevent the further proteolysis of lung tissue. Again,the ability of the compounds to inhibit cathepsin G is desirable, sincethe combination of elastase and cathepsin G has been reported to be fivetimes as efficient at degrading elastin as is elastase alone. Boudier,C., et al., J. Biol. Chem. 256, 10256 (1981). In a like manner, adultrespiratory-distress syndrome, certain skin diseases, aging, and certaininflammatory processes where the disease state is connected with thelocalized breakdown of protein by elastase could be treated by elastaseinhibitors, such as the compounds of this invention. For example,degradation of fibronectin, an important biological substance, could beinhibited. McDonald, J. A., and D. G. Kelley, J. Biol. Chem., 255, 8848(1980). The compounds may also be useful in the treatment of otherenzyme related diseases, such as fribrosis related to prolylhydroxylase,hypercholesterolemia related to HMG CoA reductase, and the like. Thisinvention is not limited to these examples as one skilled in the artcould readily apply these methods to any protease related disease orcondition.

The method of the invention can be practiced in a variety of ways andthe compounds can be administered in a number of dosage forms. Apreferred method of delivery would be in such a manner so as to localizethe action of the inhibitor. So, for example, in arthritis, thecompounds could be injected directly into the affected joint, or foremphysema, the compounds could be inhaled using an aerosol or otherappropriate spray. In any event, the compounds may be administered inany conventional manner. The compounds could be administered in oralunit dosage forms such as tablets, capsules, pills, powders or granules.They also may be administered rectally or vaginally in such forms assuppositories. They may be introduced in the forms of eyedrops,intraperitoneally, subcutaneously, or intramuscularly using forms knownto the pharmaceutical art. For the treatment of inflammatory skindiseases, the compounds of the present invention may also beadministered topically in the form of ointments, creams, gels or thelike. Regardless of the route of administration selected, the compoundsare formulated into pharmaceutically acceptable dosage forms byconventional methods known to the pharmaceutical art.

An effective but non-toxic quantity of the compound is employed intreatment. The dosage regimen for elastase inhibition by the compoundsof this invention is selected in accordance with the variety of factorsincluding the type, age, weight, sex, and medical condition of themammal, the particular disease and its severity, the route ofadministration and the particular compound employed. An ordinarilyskilled physician or veterinarian will readily determine and prescribethe effective amount of the compound to prevent or arrest the progressof the condition. In so proceeding, the physician or veterinarian couldemploy relatively low dosages at first, subsequently increasing the doseuntil a maximum response is obtained.

The compounds useful in practicing the method of this invention areprepared by methods illustrated in Charts A, B and C. Chart Aillustrates two methods used to prepare compounds of Formula XIII fromhydroxy- or alkoxy-substituted benzoic esters, Formula XI. In onemethod, compounds of Formula XI undergo Friedel-Crafts acylations withacyl halides in the presence of Lewis acids, giving compounds of FormulaXIII directly. directly. Preferred conditions include reaction with analkanoyl chloride, such as octadecanoyl chloride, in refluxingtetrahydrofuran containing aluminum chloride. In another method,compounds of Formula XI first react with acyl halides to form esterintermediates of Formula XII. Preferred conditions include reaction withan alkanoyl halide, such as octadecanoyl chloride, in tetrahydrofurancontaining a tertiary amine base, such as triethylamine. Theintermediates thus formed undergo Fries rearrangement in the presence ofLewis acids. Preferred conditions include refluxing1,1,2,2-tetrachloroethane containing aluminum chloride or heatingFormula XII and aluminum chloride without solvent.

Compounds of Formula XIII may further be modified to give othercompounds of the invention. For example, ketones of Formula XIII may beconverted to corresponding alcohols, Formula XIV, by reaction withactivated hydride reducing agents. Preferred conditions include reactionwith sodium borohydride in ethanol. Alcohols of Formula XIV may also beconverted back to ketones, Formula XIII, by reaction with suitableoxidizing agents, such as manganese dioxide. Chart B illustrates othermethods used to convert compounds of Formula XIV to additional compoundsof this invention. Alcohols of Formula XIV may be dehydrated by heatingin the presence of an acid catalyst, giving alkenes of Formula XXI.Preferred conditions include refluxing benzene or toluene containingp-toluenesulfonic acid. Alkenes of Formula XXI may be reduced tocorresponding alkanes, Formula XXII. Preferred conditions includehydrogenation in an organic solvent, such as acetic acid, over a noblemetal catalyst, such as palladium or rhodium.

Further modifications of the compounds described above can be effectedby methods known to those skilled in the art. For example, the esters ofFormula XXIII may be hydrolyzed to free acids of Formula XXIV. Preferredconditions include alkali metal hydroxides in water, followed byneutralization with a dilute mineral acid. Corresponding carboxylic acidsalts (e.g., having a metal or other positively charged counter ion) mayreadily be prepared by methods known to those skilled in the art. Arylhydroxyl groups of Formula XXV may be derivatized, for example, byconversion to alkyl ethers of Formula XXVI by reaction with alkylhalides or tosylates. Preferred conditions include heating at reflux inxylene containing potassium carbonate, with provisions to extract waterwith a Dean-Stark trap, followed by alkylation with alkyl tosylates.

Additonal methods for preparing the compounds of this invention will beapparent to those skilled in the art. For example, compounds can beprepared by methods utilizing Wittig reactions, Codogan, J. I. G., ed.,Organophosphorus Reagents in Organic Synthesis, Academic Press (London,1979), or aldol condensations, Nielson, Organic Reactions, 16, 1-444(1968); Mukaiyama, T. Organic Reactions, 28, 203-331 (1982). Chart Cillustrates the application of aldol condensation. Substitutedacetophenones of Formula XXXI react with aldehydes under basic or acidicconditions to form hydroxyketones of Formula XXXII. Dehydration ofcompounds of Formula XXXII, using methods described above (See alsoChart B), afford unsaturated ketones of Formula XXXIII. Hydrogenation ofFormula XXXIII, using methods described above (See also Chart B),affords ketones of Formula XXXIV, which are homologous to correspondingketones of Formula XIII (Chart A).

The invention will appear more fully from the Examples which follow.These Examples are given by way of illustration only and are not to beconstrued as limiting the invention either in spirit or in scope, asmany modifications both in materials and methods will be apparent fromthis disclosure to those skilled in the art. In these examples,temperatures are given in degrees celcius (°C.) and quantities ofmaterials in grams and milliliters unless otherwise noted.

DESCRIPTION OF THE PREFERRED EMBODIMENTS ##STR4## EXAMPLE 1 Ethyl4-hydroxy-3-(1-oxooctadecyl)benzoate

Ethyl p-hydroxybenzoate (16.6 g), anhydrous aluminum chloride (28 g),and steroyl chloride (30.2 g) in 100 ml of tetrachloroethylane werestirred at room temperature overnight, then heated at reflux for 5hours. The reaction mixture was added to ice/10% HCl with stirring andthe layers allowed to separate. The aqueous phase was washed with 50 mlof dichloromethane and 50 ml of ethyl acetate. The organic phases werecombined, dried over sodium sulfate, and then concentrated to dryness.The residue was chromatographed on silica gel to give the titlecompound, m.p. ca. 74° C. ##STR5##

EXAMPLE 2 Ethyl 3-(octadecanoyloxy)benzoate

Steroyl chloride (10 g) was added to 5.5 g of ethyl p-hydroxybenzoate in50 ml of tetrahydrofuran and stirred at room temperature for 4 hours.Under nitrogen, 4.6 ml of triethylamine was added with stirring in threeequal portions. The mixture was stirred at room temperature overnight,then heated at reflux for one day. The solution was cooled to roomtemperature and solvent removed under N₂, and the products trituratedwith cyclohexane. The organic layers were combined, filtered and washedwith water, 1N NaOH, 1N HCl, and water, then dried over sodium sulfate.Cyclohexane was removed under reduced pressure to give 12 g of product,m.p. ca. 57° C. ##STR6##

EXAMPLE 3 Ethyl 2-(octadecanoyloxy)benzoate

To a cold (+5° C.) solution of ethyl salicylate (0.136 moles) andstearoyl chloride (0.136 moles) in tetrahydrofuran (200 ml) was addedtriethylamine (0.136 moles) dropwise over 25 min. After refluxing for 20hours, the solution was cooled to room temperature. Most of thetetrahydrofuran was removed with a N₂ stream during the cooling process.The residue was poured into ice/water (1500 ml), stirred for 1 hour, anda white solid removed by filtration. Washing the solid with water,followed by air drying gave 56 g of the title product, m.p. 50.5°-53.5°C.

Analysis calcd for C₂₇ H₄₄ O₄ (432.64): C, 74.96; H, 10.25. Found: C,74.80; H, 10.51. ##STR7##

EXAMPLE 4 2-hydroxy-5-(1-oxooctadecyl)benzoic acid

Aluminum chloride (0.18 moles) was added in several portions to asolution of the compound from Example 3 (0.082 moles) in1,1,2,2-tetrachloroethane (350 ml). The solution was stirred for 1 hourat room temperature and refluxed for 25 hours under a N₂ atmosphere,cooled to 5° C. and poured into 10% HCl (1000 ml). After standing 20hours, methylene chloride (500 ml) was added and the layers separated.The organic layer was dried over sodium sulfate, filtered, andconcentrated to dryness in a rotary evaporator. Hexane (500 ml) wasadded to the residue and left to stand 24 hours. The resultant solid wascollected, then recrystallized from ethyl acetate. The dry solid product(10.2 g) was purified by chromatography on silica gel. Recrystallizationfrom ethyl acetate gave the title compound (9.3 g), m.p. ca. 128°-134°C. ##STR8##

EXAMPLE 5 Ethyl 4-hydroxy-3-(1-hydroxyoctadecyl)benzoate

The title compound of Example 1 (1.0 g) was dissolved in 20 ml ofabsolute ethanol, and 0.1 g NaBH₄ was added with stirring under N₂atmosphere. The reaction mixture was stirred for two hours, added to 1NHCl, and the mixture concentrated to dryness under reduced pressure togive a crystalline mass. This solid was extracted into ethyl acetate,and the extractants combined and washed with water, then dried oversodium sulfate. The solvent was removed under reduced pressure to givethe title compound, m.p. ca. 75° C. ##STR9##

EXAMPLE 6 2-hydroxy-5-(1-hydroxyoctadecyl)benzoic acid

2-Hydroxy-5-(1-oxooctadecyl)benzoic acid (1.0 g) was added to 5 mlabsolute ethanol, followed by 94 mg of NaBH₄.

The mixture was stirred at room temperature for 2 hours, then added to10 ml of 0.1N HCl to give a solid. The solid was filtered, washed with10 ml of water, dried in air and then at a pressure of 0.5 mm Hg at roomtemperature for about 65 hours to give the title compound, m.p. ca. 102°C. ##STR10##

EXAMPLE 7 2-hydroxy-5-octadec-1-enylbenzoic acid

2-Hydroxy-5-(1-hydroxyoctadecyl)benzoic acid (100 mg) was dissolved in20 ml of benzene and a trace of p-toluenesulfonic acid monohydrateadded. The solution was refluxed for 10 minutes, then 10 ml of solventwas distilled. Reflux was continued for about 18 hours. Upon cooling toroom temperature, the solution was extracted with 1% sodium bicarbonatesolution and the solvent removed under a stream of nitrogen gas to givecrystals. The material was recrystallized from methanol to give thetitle compound, m.p., ca. 95° C. ##STR11##

EXAMPLE 8 4-hydroxy-3-(1-oxooctadecyl)benzoic acid

The title compound of Example 1 (500 mg) was heated at reflux for 24hours with 230 mg of lithium hydroxide monohydrate. The reaction mixturewas cooled to room temperature, then added to 20 ml of 1N HCl withstirring, followed by the addition of 10 ml of water and 10 ml of ethylacetate. The mixture was filtered and the solid recrystallized fromdimethylformamide to give the title compound, m.p. ca. 170° C. ##STR12##

EXAMPLE 9 2-hydroxy-5-(1-oxooctadecyl)benzoic acid, monosodium salt

The title compound of Example 4 (500 mg) was dissolved in 10 ml of hotabsolute ethanol and added to 123.6 ml of 0.01N sodium hydroxide withstirring. A solid separated but stirring was continued for an additionaltwo hours. The mixture was filtered and the crystals dried overnight atroom temperature and 0.5 mm Hg, then for four hours at 75° C. and 0.5 mmHg.

Analysis calcd. for C₂₅ H₃₉ O₄ Na: C, 70.39; H, 9.21; Na, 5.28. Found:C, 70.06; H, 9.21; Na, 5.14. ##STR13##

EXAMPLE 10 2-hydroxy-5-(1-oxooctadecyl)benzoic acid, monopotassium salt

A solution of the title product of Example 4 (4.95 mmole) and potassiumacetate (4.95 mmole) in ethanol (40 ml) was heated at 65° C. for 2hours. The volume was reduced to 10 ml under a nitrogen stream and thesolution cooled in a refrigerator. The title compound was collected as awhite solid, m.p. ca. 224°-230° C. ##STR14##

EXAMPLE 11 2-hydroxy-5-(1-oxooctadecyl)benzoic acid, lysine salt

A solution of the product of Example 4 (1.24 mmole) and L-lysine (1.24mmole) in methanol (50 ml) was refluxed for 3 hours and stirred at 50°C. overnight. The solvent was removed under vacuum and the residuerecrystallized from methanol to give 400 mg of the title compound.

Analysis calcd. for C₃₁ H₅₄ N₂ O₆ (550.78): C, 67.60; H, 9.88; N, 5.09.Found: C, 67.24; H, 9.80; N, 4.91. ##STR15##

EXAMPLE 12 Methyl 2-methoxy-5-(1-oxooctadecyl)benzoate

Potassium carbonate (11.4 mmole) was added to a solution of the productof Example 4 (5.7 mmole) in 50 ml xylene, heated to reflux, and thewater formed removed with a Dean-Stark trap. After 1 hour the Dean-Starktrap was drained. The solution was cooled to room temperature and methylp-toluenesulfonate (17.1 mmole) added. The solution was heated to 70° C.for 20 hours, and refluxed for one hour to remove the water formed.After the white solid was filtered and discarded, the filtrate wasconcentrated under vacuum to a solid, which was was recrystallized fromhot hexane, to give the title compound (1.6 g), m.p. ca. 73°-74° C.

Analysis calcd. for C₂₇ H₄₄ O₄ (432.62): C, 74.95; H, 10.25. Found: C,75.19; H, 10.49. ##STR16##

EXAMPLE 13 2-methoxy-5-(1-oxooctadecyl)benzoic acid

The product of Example 12 (3.47 mmole) was added to 75 ml methanol and10 ml hot water. Lithium hydroxide (1.0 g) was added and the mixturestirred overnight at 45° C. The solvent was removed on a rotaryevaporator and 1N HCl (100 ml) and CH₂ Cl₂ (100 ml) were added to theresidue. The layers were separated and the organic layer washed withwater. The organic solution was dried with sodium sulfate, filtered, andconcentrated to a solid. The title compound, m.p. 194°-6°, was purifiedby column chromatography. ##STR17##

EXAMPLE 14 1-methylethyl 2-hydroxy-5-(1-oxooctadecyl)benzoate

A solution of the title product of Example 4 (6.2 mmole) and sulfuricacid (0.5 ml) in 120 ml of isopropyl alcohol (100 ml) was heated at 45°C. for 12 days, refluxed for 36 hours, and concentrated on a rotaryevaporator to an oil. The oil was dissolved in methylene chloride,washed with water, dried over sodium sulfate, filtered, and concentratedunder vacuum to give the title compound, m.p. 72°-73° C.

Analysis calcd. for C₂₈ H₄₆ O₄ (446.67): C, 75.29; H, 10.38. Found: C,75.26; H, 10.30. ##STR18##

EXAMPLE 15 2-hydroxy-5-(1-oxooctadecyl)benzoic acid,tris(2-hydroxyethyl)amine salt

The title compound, m.p. ca. 84°, was prepared by the method of Example10 using 500 mg of the compound of Example 4 and 184 mg oftriethanolamine. The crude product was purified by crystallization fromethanol. ##STR19##

EXAMPLE 16 2-hydroxy-5-(1-oxooctadecyl)benzoic acid, N-methylmorpholinesalt

The title compound, m.p. ca. 98°, was prepared by the method of Example10 using 500 mg of the compound of Example 4 and 125 mg ofN-methylmorpholine. The crude product was purified by crystallizationfrom ethanol. ##STR20##

EXAMPLE 17 2-hydroxy-5-(1-oxooctadecyl)benzoic acid,2-hydroxy-N,N,N-trimethyl ethanaminium salt

The title compound was prepared by the method of Example 10 using 1.0 gof the compound of Example 4 and 630 mg cholinechloride. After removalof the resultant potassium chloride precipitate, the crude product waspurified by crystallization from ethanol.

Analysis calcd. for C₃₀ H₅₃ NO₅ : 1/2H₂ O: C, 69.73; H, 10.53; N, 2.71.Found: C, 69.45; H, 10.49; N, 3.08

EXAMPLE 18

The compound 2-hydroxy-5-(1-oxooctadecyl)benzoic acid, monopotassiumsalt was screened in the collagen-induced rat arthritis model describedabove.

The test compound retarded the progression of the arthritis whenassessed by inflammatory swelling at the lesion site. Results werestatistically significant (P=0.001). ##STR21##

We claim:
 1. Compounds of the formula:wherein R₁ is: (a) hydrogen; or(b) alkyl of 1 to 6 carbon atoms, inclusive;wherein R₂ is: (a) hydroxy;or (b) alkoxy of 1 to 6 carbon atoms, inclusive;wherein R₃ is --CH═CHR₄wherein R₄ is alkyl of 13 to 25 carbon atoms inclusive or thepharmacologically acceptable addition salts thereof.
 2. A compoundaccording to claim 1 wherein the compound is2-hydroxy-5-octadec-1-enylbenzoic acid.